Current Treatment Options in Neurology

, Volume 9, Issue 3, pp 205–209 | Cite as

Treatment of levodopa-induced dyskinesia

  • Jayaraman Rao
Movement Disorders


Levodopa Clozapine Deep Brain Stimulation Quetiapine Amantadine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Mayeux R:Epidemiology of neurodegeneration.Ann Rev Neurosci 2003, 26:81–104.PubMedCrossRefGoogle Scholar
  2. 2.
    de Lau LM:Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study.Neurology 2004, 63:1240–1244.PubMedGoogle Scholar
  3. 3.
    Of importance Rao J:Neurochemistry of nigral degeneration. InHandbook of Parkinson’s Disease. Edited by Pahwa R, Lyons KE. New York: Futura; 2007: In press. A review of molecular mechanisms that may make the ventral tier of dopaminergic neurons of substantia nigra pars compacta more vulnerable to degeneration than the ventral tegmental area dopaminergic neurons.Google Scholar
  4. 4.
    Of major importance Rao J:Neurochemistry of Parkinson’s disease. InParkinson’s Disease and Related Disorders. Handbook of Clinical Neurology Series. Edited by Koller WC, Malamed E. New York: Elsevier; 2007: In Press. A detailed discussion of neurochemical changes in dopaminergic and nondopaminergic systems in PD.Google Scholar
  5. 5.
    Rascol O:A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group.N Engl J Med 2000, 342:1484–1491.PubMedCrossRefGoogle Scholar
  6. 6.
    Rascol O:Development of dyskinesias in a 5-year trial of ropinirole and L-dopa.Mov Disord 2006, 21:1844–1850.PubMedCrossRefGoogle Scholar
  7. 7.
    Ahlskog JE:Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature.Mov Disord 2001, 16:448–458.PubMedCrossRefGoogle Scholar
  8. 8.
    Linazasoro G:New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity.Trends Pharmacol Sci 2005, 26:391–397.PubMedCrossRefGoogle Scholar
  9. 9.
    Of major importance Jankovic J:Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations.Mov Disord 2005, 20(Suppl 11):S11-S16. A comprehensive review of clinical features of motor fluctuations in PD.PubMedCrossRefGoogle Scholar
  10. 10.
    Pechevis M:Effects of dyskinesias in Parkinson’s disease on quality of life and health-related costs: a prospective European study.Eur J Neurol 2005, 12:956–963.PubMedCrossRefGoogle Scholar
  11. 11.
    Of major importance Samadi P:Opioids and motor complications in Parkinson’s disease.Trends Pharmacol Sci 2006, 27:512–517. An excellent analysis of the role played by opioids in dyskinesia in animal models of PD.PubMedCrossRefGoogle Scholar
  12. 12.
    Cenci MA:L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA.Eur J Neurosci 1998, 10:2694–2706.PubMedCrossRefGoogle Scholar
  13. 13.
    Johansson PA:Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of 1-DOPA-induced dyskinesia.Neurobiol Dis 2001, 8:220–239.PubMedCrossRefGoogle Scholar
  14. 14.
    Hallett PJ:Rationale for and use of NMDA receptor antagonists in Parkinson’s disease.Pharmacol Ther 2004, 102:155–174.PubMedCrossRefGoogle Scholar
  15. 15.
    Of major importance Chen HS:The chemical biology of clnically tolerated NMDA receptor antagonists.J Neurochem 2006, 97:1611–1626. Excellent review of the mechanisms of actions of NMDA antagonists, especially that of memantine.PubMedCrossRefGoogle Scholar
  16. 16.
    Nicholson SL:5-hydroxytryptamine (5-HT, serotonin) and Parkinson’s disease-opportunities for novel therapeutics to reduce the problems of levodopa therapy.Eur J Neurol 2002, 9(Suppl 3):1–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Of importance Brotchie JM:Nondopaminergic mechanisms in levodopa-induced dyskinesia.Mov Disord 2005, 20:919–931. A good review of the nondopaminergic mechanisms underlying levodopa-induced dyskinesia.PubMedCrossRefGoogle Scholar
  18. 18.
    Colosimo C:Noradrenergic drugs for levodopa-induced dyskinesia.Clin Neuropharmacol 2003, 26:299–305.PubMedCrossRefGoogle Scholar
  19. 19.
    Of major importance Metman LV:Role of surgery in the treatment of motor complications.Mov Disord 2005, 20(Suppl 11):S45-S56. An excellent review of the role of DBS surgery in motor complications.PubMedCrossRefGoogle Scholar
  20. 20.
    Fraix V:Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson’s disease. 2000.Neurology 2001, 57:S60-S62.PubMedGoogle Scholar
  21. 21.
    Metman LV:Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study.Arch Neurol 1999, 56:1383–1386.PubMedCrossRefGoogle Scholar
  22. 22.
    Reis J:Modulation of human motor cortex excitability by single doses of amantadine.Neuropsychopharmacology 2006, 31:2758–2766.PubMedCrossRefGoogle Scholar
  23. 23.
    Kornhuber J:Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study.Eur J Pharmacol 1991, 206:297–300.PubMedCrossRefGoogle Scholar
  24. 24.
    Kornhuber J:Affinity of 1-aminoadamantanes for the sigma binding site in post-mortem human frontal cortex.Neurosci Lett 1993, 163:129–131.PubMedCrossRefGoogle Scholar
  25. 25.
    Rajput AH:Amantadine ameliorates levodopa induced dyskinesia.Neurology 1997, 48:A328.Google Scholar
  26. 26.
    Of major importance Nutt JG:Continuous dopaminergic stimulation: Is it the answer to the motor complications of levodopa? Mov Disord 2007, 22:1–9. A careful analysis of the validity of the “continuous dopaminergic stimulation” concept.PubMedCrossRefGoogle Scholar
  27. 27.
    Katzenschlager R:Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson’s disease: a prospective study using single-dose challenges.Mov Disord 2005, 20:151–157.PubMedCrossRefGoogle Scholar
  28. 28.
    Of major importance Zanettini R:Valvular heart disease and the use of dopamine agonists for Parkinson’s disease.N Engl J Med 2007, 356:39–46. The link between ergot-derived dopamine agonists and their causal relationship with cardiac valvular disease is reinforced with additional cases.PubMedCrossRefGoogle Scholar
  29. 29.
    Durif F:Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study.Neurology 2004, 62:381–388.PubMedGoogle Scholar
  30. 30.
    Of major importance Dean B, Scarr E:Antipsychotic drugs: evolving mechanisms of action with improved therapeutic benefits.Curr Drug Targets CNS Neurol Disord 2004, 3:217–225. A good synposis of the mechanisms of action of atypical antipsychotics.PubMedCrossRefGoogle Scholar
  31. 31.
    Baron MS:Quetiapine as treatment for dopaminergic-induced dyskinesias in Parkinson’s disease.Mov Disord 2003, 18:1208–1209.PubMedCrossRefGoogle Scholar
  32. 32.
    Katzenschlager R, Manson AJ, Evans A, et al.:Low dose quetiapine for drug induced dyskinesias in Parkinson’s disease: a double blind cross over study.J Neurol Neurosurg Psychiatry 2004, 75:295–297.PubMedGoogle Scholar
  33. 33.
    Of major importance Pahwa R:Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.Neurology 2006, 66:983–995. An evidence-based review of medical and surgical treatment of dyskinesia and motor fluctuations.PubMedCrossRefGoogle Scholar
  34. 34.
    Of major importance Fraix V:Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson’s disease.J Neurol Neurosurg Psychiatry 2006, 77:443–449. A good discussion of economic consequences of DBS in PD.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  1. 1.Parkinson’s Disease and Movement Disorders Center, Department of NeurologyOchsner Foundation ClinicNew OrleansUSA

Personalised recommendations